Schizophrenia is a chronic, severe and recurrent brain disorder that requires continuous, long-term treatment with antipsychotic medication to minimize relapse and provide clinical benefit to patients. 1 For patients with schizophrenia, non-adherence to medication is a major risk factor for relapse and re-hospitalization. 2 Long-acting Injectable (LAI) formulations of atypical antipsychotics provide constant medication delivery and the potential for improved adherence. 1
The clinical trial treatment effect for PP was based on relative relapse risk and calculated based on Gaebel et al 2010 (establishing relative relapse risks for RLAI vs QUE over 2 years) and Leucht et al 2009 (reporting evidence of similar relapse risk for QUE and HAL), thereby allowing to apply the NICE relative risk ratio for HAL over placebo to generate the relative relapse risk for RLAI over placebo: [(RLAI/QUE Gaebel ) *(QUE/HAL Leucht )*(HAL/PLC NICE ) = RLAI/placebo in model]. [3] [4] [5] Because lack of clinical studies with PP and OP, relapse risk ratio was estimated using the head-tohead trial of OP and olanzapine oral. Relapse rates by treatment arms are presented in table 2.
Compliance
The compliance data for the general schizophrenia population were derived from Gilmer 20046 and Olivares et al 20097: PP and OP are assumed to have the same risk as RLAI, RLAI risk ratio (1.29) is based on Olivares et al 20097, leading to a compliance rate of 52.9 (1.29*41% = 52.9%, with 41% being the proportion of compliant patients in the general population (Gilmer 2004 ). The same approach was applied for the risk for non-compliance (Olivares 2007) however, due to estimated compliance issues RLAI vs. AAP Hazard ratio was discounted by proportion of non-compliant patients (0.17*24%=4.1%).6 The probability and risk ratio for partially compliant patients was then calculated using the other risks. (Table 2 ) It was assumed that the compliance level of PP is equal to risperidone long-acting injection. Regarding compliance level of OP, it was decided it would not be higher than on PP because of the strong monitoring requirements for patients receiving OP. Because no evidence or studies that 3-hour post-monitoring of OP would decrease the compliance level it was assumed that compliance level of OP is equal to PP.
Side-effects
Antipsychotic drugs are associated with dose-dependent risks of extrapyramidal symptoms, tardive dyskinesia, weight gain and diabetes. Annual probabilities of side-effects with OP were assumed to be equal to oral olanzapine. Sideeffects probabilities for PP and OP are presented in table 3.
Switch rates
Switch rates are dependent on treatment and health states. Four possible reasons for switches were distinguished: Lack of efficacy, lack of compliance, side-effects, patient request. The probability of switch due to lack of efficacy was assumed to affect patients with relapse only. Therefore, the probability of switch due to lack of efficacy among patients with relapse was calculated as the ratio of the probability of switch due to lack of efficacy over the probability of relapse in any cycle.
Utilities
Since we were unable to find a study reporting on utility data from Swedish schizophrenia patients, utility scores for health states and utility decrements for side-effects were taken from a UK study Briggs et al. 2008 . 12 
Treatment strategies
The treatment strategies used in the analyses: Third line and last line of treatment was clozapine.
RESULTS
All results are provided for a time horizon of 55 years. The discount rates for costs, QALYs and relapses were set to 3%. Costs were reported in 2010 Swedish kronor (1 SEK ≈ 0.159 Euro). In tables 5 and 6, total costs, discounted QALYs and discounted relapses are shown. Paliperidone palmitate dominates olanzapine pamoate by being less costly and more effective.
Probabilistic sensitivity analysis
• A PSA was run including 12 different parameters for which distributions had been defined. The PSA was run with 1.000 simulations to compare the cost-effectiveness between PP and OP.
• QALYs gained: OP dominates PP in only 1% of simulations. Conversely PP dominates OP in 99% of cases (picture 2).
• Relapses avoided: PP is dominated by OP in 8% and dominates OP in about 92% of cases (picture 3).
Limitations
There is a lack of head-to-head clinical trial data comparing paliperidone palmitate and olanzapine pamoate.
Conclusions
• This cost-effectiveness analysis suggests that use of paliperidone palmitate resulted in improved clinical outcomes and lower health care costs compared with olanzapine pamoate • Paliperidone palmitate leads to fewer relapses and greater QALYs gained compared with olanzapine pamoate
• Paliperidone palmitate appears to be a cost-effective treatment option vs olanzapine pamoate for patients with schizophrenia
After paliperidone palmitate After olanzapine pamoate
• olanzapine pamoate
• clozapine
• perphenazine
• zyclopenthixol
• oral olanzapine
• risperidone LAI
Sensitivity analysis
One-way sensitivity analyses were performed where one input was changed while others were left unchanged. (Table 7) The model is sensitive essentially to the risk ratio of relapse and the proportion of patients changing medication. Side effects parameters appeared most influential on ICER for QALY while switch rates appeared to have greater impact in ICER for relapse. 
